0001193125-26-205182
SEC filingQ1 2026 was a transformative but costly quarter as Minerva initiated its confirmatory Phase 3 C19 trial, driving a sharp increase in operating losses and a massive non-cash warrant liability charge.
Research and development expenses increased due to the initiation of the confirmatory Phase 3 C19 trial and higher compensation costs. This drove operating income to -$16.7 million for the three months ended March 31, 2026, compared to -$3.9 million in the prior year period. The operating loss widened by 327.2% year-over-year.
Net income was -$125.4 million, a significant decline from -$3.8 million in Q1 2025. The decrease was primarily attributable to a non-cash loss from the revaluation of warrant liability, which is tied to the company's stock price and trial progress. This charge created volatility in reported earnings and is expected to continue in future periods.
Net cash used in operating activities was -$5.4 million, compared to -$4.1 million in the prior year, reflecting increased spending on the C19 trial. The company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. Management expects to require additional capital to continue advancing the development, regulatory approval process, and potential commercialization of roluperidone and other product candidates.
The company's outlook is heavily dependent on the success of the C19 trial, with topline efficacy results expected in the second half of 2027. The warrant liability will continue to create volatility in reported earnings, as its fair value fluctuates with the stock price and trial progress. The company also faces the risk of needing additional capital, as highlighted in the risk factors. The settlement with Geoffrey Race, including a consultancy agreement, adds to near-term costs but resolves a key personnel transition.